Posted innews OB/GYN & Women’s Health Oncology
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.